Sevelamer Hydrochloride Tablet Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 400 mg, 800 mg

Reference Brands: Renagel (USA)

Category: Nephrology

Sevelamer Hydrochloride is a non-calcium, non-metal-based phosphate binder used to control serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis. It works by binding phosphate from dietary sources in the gastrointestinal tract, preventing its absorption into the bloodstream. This helps reduce hyperphosphatemia and supports better management of kidney-related complications. Sevelamer Hydrochloride Tablet is available in Tablet and strengths such as 400 mg, 800 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Sevelamer Hydrochloride Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Sevelamer Hydrochloride Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Sevelamer is a phosphate-binding medication used to manage hyperphosphatemia in patients with chronic kidney disease, particularly those on dialysis. It works by binding to dietary phosphate in the gastrointestinal tract when taken with meals, preventing its absorption and helping to maintain balanced phosphate levels in the blood. This action reduces the risk of complications associated with high phosphate levels, such as bone and cardiovascular disorders. Sevelamer was originally invented and developed by GelTex Pharmaceuticals and is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate). Available in oral formulations, sevelamer provides a non-calcium, non-metal-based option for controlling hyperphosphatemia, offering an effective and well-tolerated approach for long-term management in chronic kidney disease patients. Its use supports better overall patient outcomes by helping to regulate phosphate levels safely without adding extra calcium or aluminum load.